A carregar...
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
Ixazomib, the first oral proteasome inhibitor, is approved in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy. Ixazomib is a selective, potent, and reversible inhibitor of the 20S proteasome, and pr...
Na minha lista:
| Publicado no: | Clin Pharmacokinet |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6397141/ https://ncbi.nlm.nih.gov/pubmed/30117017 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-018-0702-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|